200 related articles for article (PubMed ID: 35819095)
1. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
Mukai Y; Yoshida Y; Yoshida T; Kondo T; Inotsume N; Toda T
Ther Drug Monit; 2021 Jun; 43(3):386-393. PubMed ID: 33065614
[TBL] [Abstract][Full Text] [Related]
3. Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
Sumimoto T; Nakahara R; Suzuki Y; Tanaka R; Yoshida N; Ogata M; Itoh H
Ther Drug Monit; 2022 Jun; 44(3):419-429. PubMed ID: 34469417
[TBL] [Abstract][Full Text] [Related]
4. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
5. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
6. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
[TBL] [Abstract][Full Text] [Related]
7. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
Miura M; Takahashi N
Rinsho Ketsueki; 2019; 60(9):1140-1147. PubMed ID: 31597837
[TBL] [Abstract][Full Text] [Related]
8. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
11. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Deb S; Boknäs N; Sjöström C; Tharmakulanathan A; Lotfi K; Ramström S
Cancer Med; 2020 Jan; 9(1):313-323. PubMed ID: 31714021
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia].
Usui N
Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
14. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
15. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
16. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S; Eskazan AE; Suzan V; Savci S; Erdogan Ozunal I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Erbilgin Y; Iseri SA; Ar MC; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Hematology; 2018 May; 23(4):212-220. PubMed ID: 28990873
[TBL] [Abstract][Full Text] [Related]
17. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.
Zhao D; Long X; Wang J
BMC Pharmacol Toxicol; 2024 Feb; 25(1):20. PubMed ID: 38395895
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
Moslehi JJ; Deininger M
J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
[TBL] [Abstract][Full Text] [Related]
19. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
20. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
